Basal cell carcinomas: Attack of the hedgehog

Nature Reviews Cancer

Volumn 8, Issue 10, 2008, Pages 743-754

  Epstein, Ervin H ^a  

^a CHILDREN S HOSPITAL OAKLAND RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARBOPLATIN; CELECOXIB; CURIS 61414; CYCLOPAMINE; IMATINIB; PACLITAXEL; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN INTERACTING WITH PROTEIN KINASE C; RETINOID; SONIC HEDGEHOG PROTEIN; SORAFENIB; SUNSCREEN; TAZAROTENE; TRANSCRIPTION FACTOR; TRANSCRIPTION FACTOR FOXM1; UNCLASSIFIED DRUG; WNT PROTEIN;

ACNE; ANTINEOPLASTIC ACTIVITY; BASAL CELL CARCINOMA; BASAL CELL NEVUS SYNDROME; CANCER GROWTH; CANCER INHIBITION; CANCER SURGERY; CLINICAL TRIAL; COLORECTAL CANCER; DNA DAMAGE; DNA REPAIR; DRUG BINDING; DRUG INHIBITION; GENE MUTATION; GENETIC IDENTIFICATION; GENETIC PREDISPOSITION; GENETIC VARIABILITY; HUMAN; METASTASIS; MOLECULAR GENETICS; MULTIMODALITY CANCER THERAPY; NONHUMAN; OVARY CANCER; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PROTEIN FUNCTION; REVIEW; SIGNAL TRANSDUCTION; SKIN CARCINOGENESIS; SOMATIC MUTATION; XERODERMA PIGMENTOSUM;

ANIMALS; ANTINEOPLASTIC AGENTS; BASAL CELL NEVUS SYNDROME; CARCINOMA, BASAL CELL; GENETIC PREDISPOSITION TO DISEASE; HEDGEHOG PROTEINS; HUMANS; MICE; RECEPTORS, CELL SURFACE; SIGNAL TRANSDUCTION; SKIN NEOPLASMS; UNITED STATES;

EID: 52649111039     PISSN: 1474175X     EISSN: 14741768     Source Type: Journal    
DOI: 10.1038/nrc2503     Document Type: Review

References (199)

1. Miller, D. L. Nonmelanoma skin cancer in the United States: incidence. J. Am. Acad. Dermatol. 30, 774-778 (1994).
2. Housman, T. S. et al. Skin cancer is among the most costly of all cancers to treat for the Medicare population. J. Am. Acad. Dermatol. 48, 425-429 (2003).
3. Rubin, A. I., Chen, E. H. & Ratner, D. Basal-cell carcinoma. N. Eng. J. Med. 353, 2262-2269 (2005). This paper gives an authoritative, more complete review of the more clinical aspects of this tumour.
4. Karagas, M. R. et al. Use of tanning devices and risk of basal cell and squamous cell skin cancers. J. Natl Cancer Inst. 94, 224-226 (2002).
5. Marcil, I. & Stern, R. S. Risk of developing a subsequent nonmelanoma skin cancer in patients with a history of nonmelanoma skin cancer: a critical review of the literature and meta-analysis. Arch. Dermatol. 136, 1524-1530 (2000).
6. Karagas, M. R. et al. Risk of subsequent basal cell carcinoma and squamous cell carcinoma of the skin among patients with prior skin cancer. JAMA 267, 3305-3310 (1992).
7. Chuang, T. Y., Reizner, G. T., Elpern, D. J., Stone, J. L. & Farmer, E. R. Nonmelanoma skin cancer in Japanese ethnic Hawaiians in Kauai, Hawaii: an incidence report. J. Am. Acad. Dermatol. 33, 422-426 (1995).
8. Chuang, T. Y., Reizner, G. T., Elpern, D. J., Stone, J. L. & Farmer, E. R. Non-melanoma skin cancer and keratoacanthoma in Filipinos: an incidence report from Kauai, Hawaii. Int. J. Dermatol. 32, 717-718 (1993).
9. Hoshida, Y. et al. Cancer risk after renal transplantation in Japan. Int. J. Cancer 71, 517-520 (1997).
10. Kricker, A., Armstrong, B. K., English, D. R. & Heenan, P. J. Does intermittent sun exposure cause basal cell carcinoma? A case-control study in Western Australia. Int. J. Cancer 60, 489-494 (1995).
11. Rosso, S. et al. The multicentre south European study 'Helios'. II: Different sun exposure patterns in the aetiology of basal cell and squamous cell carcinomas of the skin. Br. J. Cancer 73, 1447-1454 (1996).
12. Thompson, S. C., Jolley, D. & Marks, R. Reduction of solar keratoses by regular sunscreen use. N. Engl. J. Med. 329, 1147-1151 (1993).
13. Pandeya, N., Purdie, D. M., Green, A. & Williams, G. Repeated occurrence of basal cell carcinoma of the skin and multifailure survival analysis: follow-up data from the Nambour Skin Cancer Prevention Trial. Am. J. Epidemiol. 161, 748-754 (2005).
14. van der Pols, J. C., Williams, G. M., Pandeya, N., Logan, V. & Green, A. C. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol. Biomarkers Prev. 15, 2546-2548 (2006).
15. Kricker, A., Armstrong, B. K., English, D. R. & Heenan, P. J. A dose-response curve for sun exposure and basal cell carcinoma. Int. J. Cancer 60, 482-488 (1995).
16. Guo, H. R., Yu, H. S., Hu, H. & Monson, R. R. Arsenic in drinking water and skin cancers: cell-type specificity (Taiwan, ROC). Cancer Causes Control 12, 909-916 (2001).
17. Karagas, M. R. et al. Skin cancer risk in relation to toenail arsenic concentrations in a US population-based case-control study. Am. J. Epidemiol. 153, 559-565 (2001).
18. Karagas, M. R., Stukel, T. A. & Tosteson, T. D. Assessment of cancer risk and environmental levels of arsenic in New Hampshire. Int. J. Hyg. Environ. Health 205, 85-94 (2002).
19. Gailani, M. R. et al. Developmental defects in Gorlin syndrome related to a putative tumor suppressor gene on chromosome 9. Cell 69, 111-117 (1992).
20. Hahn, H. et al. Mutations of the human homologue of Drosophila patched in the nevoid basal cell carcinoma syndrome. Cell 85, 841-851 (1996).
21. Johnson, R. L. et al. Human homolog of patched, a candidate gene for the basal cell nevus syndrome. Science 272, 1668-1671 (1996). References 19-21 provide the original data linking basal cell carcinogenesis to aberrant activation of HH signalling.
22. Klein, R. D., Dykas, D. J. & Bale, A. E. Clinical testing for the nevoid basal cell carcinoma syndrome in a DNA diagnostic laboratory. Genet. Med. 7, 611-619 (2005).
23. Ling, G. et al. PATCHED and p53 gene alterations in sporadic and hereditary basal cell cancer. Oncogene 20, 7770-7778 (2001).
24. Ouhtit, A. et al. UV-radiation-specific p53 mutation frequency in normal skin as a predictor of risk of basal cell carcinoma. J. Natl Cancer Inst. 90, 523-531 (1998).
25. Hutchin, M. E. et al. Sustained Hedgehog signaling is required for basal cell carcinoma proliferation and survival: conditional skin tumorigenesis recapitulates the hair growth cycle. Genes Dev. 19, 214-223 (2005). This paper illustrates the requirement for continued HH signalling for BCC maintenance in a murine model of HH-driven BCC carcinogenesis.
26. Adolphe, C., Hetherington, R., Ellis, T. & Wainwright, B. Patched1 functions as a gatekeeper by promoting cell cycle progression. Cancer Res. 66, 2081-2088 (2006).
27. Gailani, M. R. et al. The role of the human homologue of Drosophila patched in sporadic basal cell carcinomas. Nature Genet. 14, 78-81 (1996).
28. Aszterbaum, M. et al. Identification of mutations in the human PATCHED gene in sporadic basal cell carcinomas and in patients with the basal cell nevus syndrome. J. Invest. Dermatol. 110, 885-888 (1998).
29. Xie, J. et al. Activating Smoothened mutations in sporadic basal-cell carcinoma. Nature 391, 90-92 (1998).
30. Reifenberger, J. et al. Missense mutations in SMOH in sporadic basal cell carcinomas of the skin and primitive neuroectodermal tumors of the central nervous system. Cancer Res. 58, 1798-1803 (1998).
31. Lum, L. & Beachy, P. A. The Hedgehog response network: sensors, switches, and routers. Science 304, 1755-1759 (2004).
32. Rohatgi, R. & Scott, M. P. Patching the gaps in Hedgehog signalling. Nature Cell Biol. 9, 1005-1009 (2007).
33. Varjosalo, M. & Taipale, J. Hedgehog signaling. J. Cell Sci. 120, 3-6 (2007).
34. Kinzler, K. W. et al. Identification of an amplified, highly expressed gene in a human glioma. Science 236, 70-73 (1987).
35. Bhatia, N. et al. Gli2 is targeted for ubiquitination and degradation by β-TrCP ubiquitin ligase. J. Biol. Chem. 281, 19320-19326 (2006).
36. Huntzicker, E. G. et al. Dual degradation signals control Gli protein stability and tumor formation. Genes Dev. 20, 276-281 (2006).
37. Jiang, J. Regulation of Hh/Gli signaling by dual ubiquitin pathways. Cell Cycle 5, 2457-2463 (2006).
38. Pan, Y., Bai, C. B., Joyner, A. L. & Wang, B. Sonic hedgehog signaling regulates Gli2 transcriptional activity by suppressing its processing and degradation. Mol. Cell. Biol. 26, 3365-3377 (2006).
39. Huangfu, D. et al. Hedgehog signalling in the mouse requires intraflagellar transport proteins. Nature 426, 83-87 (2003).
40. Huangfu, D. & Anderson, K. V. Cilia and Hedgehog responsiveness in the mouse. Proc. Natl Acad. Sci. USA 102, 11325-11330 (2005).
41. Corbit, K. C. et al. Vertebrate Smoothened functions at the primary cilium. Nature 437, 1018-1021 (2005).
42. May, S. R. et al. Loss of the retrograde motor for IFT disrupts localization of Smo to cilia and prevents the expression of both activator and repressor functions of Gli. Dev. Biol. 287, 378-389 (2005).
43. Rohatgi, R., Milenkovic, L. & Scott, M. P. Patched1 regulates hedgehog signaling at the primary cilium. Science 317, 372-376 (2007).
44. Bonifas, J. M. et al. Activation of expression of hedgehog target genes in basal cell carcinomas. J. Invest. Dermatol. 116, 739-742 (2001).
45. Tojo, M., Kiyosawa, H., Iwatsuki, K. & Kaneko, F. Expression of a sonic hedgehog signal transducer, hedgehog-interacting protein, by human basal cell carcinoma. Br. J. Dermatol. 146, 69-73 (2002).
46. Ashton, K. J., Weinstein, S. R., Maguire, D. J. & Griffiths, L. R. Molecular cytogenetic analysis of basal cell carcinoma DNA using comparative genomic hybridization. J. Invest. Dermatol. 117, 683-686 (2001).
47. Reifenberger, J. et al. Somatic mutations in the PTCH, SMOH, SUFUH and TP53 genes in sporadic basal cell carcinomas. Br. J. Dermatol. 152, 43-51 (2005).
48. Lindstrom, E., Shimokawa, T., Toftgard, R. & Zaphiropoulos, P. G. PTCH mutations: distribution and analyses. Hum. Mutat. 27, 215-219 (2006).
49. Bodak, N. et al. High levels of patched gene mutations in basal-cell carcinomas from patients with xeroderma pigmentosum. Proc. Natl Acad. Sci. USA 96, 5117-5122 (1999).
50. Daya-Grosjean, L. & Sarasin, A. UV-specific mutations of the human patched gene in basal cell carcinomas from normal individuals and xeroderma pigmentosum patients. Mutat. Res. 450, 193-199 (2000).
51. Couve-Privat, S., Bouadjar, B., Avril, M. F., Sarasin, A. & Daya-Grosjean, L. Significantly high levels of ultraviolet-specific mutations in the smoothened gene in basal cell carcinomas from DNA repair-deficient xeroderma pigmentosum patients. Cancer Res. 62, 7186-7189 (2002).
52. Moriwaki, S., Ray, S., Tarone, R. E., Kraemer, K. H. & Grossman, L. The effect of donor age on the processing of UV-damaged DNA by cultured human cells: reduced DNA repair capacity and increased DNA mutability. Mutat. Res. 364, 117-123 (1996).
53. Rees, J. L. The genetics of sun sensitivity in humans. Am. J. Hum. Genet. 75, 739-751 (2004). This remains an authoritative review of genetic factors predisposing to UV-induced skin cancers.
54. Han, J., Kraft, P., Colditz, G. A., Wong, J. & Hunter, D. J. Melanocortin 1 receptor variants and skin cancer risk. Int. J. Cancer 119, 1976-1984 (2006).
55. Liboutet, M. et al. MC1R and PTCH gene polymorphism in French patients with basal cell carcinomas. J. Invest. Dermatol. 126, 1510-1517 (2006).
56. Box, N. F. et al. Melanocortin-1 receptor genotype is a risk factor for basal and squamous cell carcinoma. J. Invest. Dermatol. 116, 224-229 (2001).
57. Bastiaens, M. T. et al. Melanocortin-1 receptor gene variants determine the risk of nonmelanoma skin cancer independently of fair skin and red hair. Am. J. Hum. Genet. 68, 884-894 (2001).
58. Gerstenblith, M. R., Goldstein, A. M., Fargnoli, M. C., Peris, K. & Landi, M. T. Comprehensive evaluation of allele frequency differences of MC1R variants across populations. Hum. Mutat. 28, 495-505 (2007).
59. Palmer, J. S. et al. Melanocortin-1 receptor polymorphisms and risk of melanoma: is the association explained solely by pigmentation phenotype? Am. J. Hum. Genet. 66, 176-186 (2000).
60. Kennedy, C. et al. Melanocortin 1 receptor (MC1R) gene variants are associated with an increased risk for cutaneous melanoma which is largely independent of skin type and hair color. J. Invest. Dermatol. 117, 294-300 (2001).
61. Slominski, A., Paus, R. & Wortsman, J. Can some melanotropins modulate keratinocyte proliferation? J. Invest. Dermatol. 97, 747 (1991).
62. Wintzen, M., Yaar, M., Burbach, J. P. & Gilchrest, B. A. Proopiomelanocortin gene product regulation in keratinocytes. J. Invest. Dermatol. 106, 673-678 (1996).
63. Corre, S. et al. UV-induced expression of key component of the tanning process, the POMC and MC1R genes, is dependent on the p-38-activated upstream stimulating factor-1 (USF-1). J. Biol. Chem. 279, 51226-51233 (2004).
64. Cui, R. et al. Central role of p53 in the suntan response and pathologic hyperpigmentation. Cell 128, 853-864 (2007).
65. Gudbjartsson, D. F. et al. ASIP and TYR pigmentation variants associate with cutaneous melanoma and basal cell carcinoma. Nature Genet. 40, 886-891 (2008). This is a recent large-scale survey of genetic variants predisposing to BCC carcinogenesis.
66. Kraemer, K. H., Lee, M. M., Andrews, A. D. & Lambert, W. C. The role of sunlight and DNA repair in melanoma and nonmelanoma skin cancer. Arch. Dermatol. 130, 1018-1021 (1994).
67. Berwick, M. & Vineis, P. Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J. Natl Cancer Inst. 92, 874-897 (2000).
68. Wei, Q., Matanoski, G. M., Farmer, E. R., Hedayati, M. A. & Grossman, L. DNA repair capacity for ultraviolet light-induced damage is reduced in peripheral lymphocytes from patients with basal cell carcinoma. J. Invest. Dermatol. 104, 933-936 (1995).
69. Dybdahl, M., Frentz, G., Vogel, U., Wallin, H. & Nexo, B. A. Low DNA repair is a risk factor in skin carcinogenesis: a study of basal cell carcinoma in psoriasis patients. Mutat. Res. 433, 15-22 (1999).
70. Segerback, D., Strozyk, M., Snellman, E., & Hemminki, K. Repair of UV dimers in skin DNA of patients with basal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 17, 2388-2392 (2008).
71. Han, S. et al. DNA repair gene XRCC3 polymorphisms and cancer risk: a meta-analysis of 48 case-control studies. Eur. J. Hum. Genet. 14, 1136-1144 (2006).
72. Han, J., Colditz, G. A., Samson, L. D. & Hunter, D. J. Polymorphisms in DNA double-strand break repair genes and skin cancer risk. Cancer Res. 64, 3009-3013 (2004).
73. Thirumaran, R. K. et al. Single nucleotide polymorphisms in DNA repair genes and basal cell carcinoma of skin. Carcinogenesis 27, 1676-1681 (2006).
74. Jacobsen, N. R. et al. No association between the DNA repair gene XRCC3 T241M polymorphism and risk of skin cancer and breast cancer. Cancer Epidemiol. Biomarkers Prev. 12, 584-585 (2003).
75. Festa, F. et al. Basal cell carcinoma and variants in genes coding for immune response, DNA repair, folate and iron metabolism. Mutat. Res. 574, 105-111 (2005).
76. Chen, Y. C. et al. Genetic polymorphism in p53 codon 72 and skin cancer in southwestern Taiwan. J. Environ. Sci. Health A Tox Hazard Subst. Environ. Eng. 38, 201-211 (2003).
77. Han, J., Cox, D. G., Colditz, G. A. & Hunter, D. J. The p53 codon 72 polymorphism, sunburns, and risk of skin cancer in US Caucasian women. Mol. Carcinog. 45, 694-700 (2006).
78. Stefanaki, I. et al. p53 codon 72 Pro homozygosity increases the risk of cutaneous melanoma in individuals with dark skin complexion and among noncarriers of melanocortin 1 receptor red hair variants. Br. J. Dermatol. 156, 357-362 (2007).
79. McGregor, J. M. et al. Relationship between p53 codon 72 polymorphism and susceptibility to sunburn and skin cancer. J. Invest. Dermatol. 119, 84-90 (2002).
80. Wilkening, S. et al. No association between MDM2 SNP309 promoter polymorphism and basal cell carcinoma of the skin. Br. J. Dermatol. 157, 375-377 (2007).
81. Asplund, A. et al. PTCH codon 1315 polymorphism and risk for nonmelanoma skin cancer. Br. J. Dermatol. 152, 868-873 (2005).
82. Wakabayashi, Y., Mao, J. H., Brown, K., Girardi, M. & Balmain, A. Promotion of Hras-induced squamous carcinomas by a polymorphic variant of the Patched gene in FVB mice. Nature 445, 761-765 (2007).
83. Yoon, J. W. et al. Gene expression profiling leads to identification of GLI1-binding elements in target genes and a role for multiple downstream pathways in GLI1-induced cell transformation. J. Biol. Chem. 277, 5548-5555 (2002).
84. Howell, B. G. et al. Microarray profiles of human basal cell carcinoma: insights into tumor growth and behavior. J. Dermatol. Sci. 39, 39-51 (2005).
85. O'Driscoll, L. et al. Investigation of the molecular profile of basal cell carcinoma using whole genome microarrays. Mol. Cancer 5, 74 (2006).
86. Yu, M. et al. Superficial, nodular, and morpheiform basal-cell carcinomas exhibit distinct gene expression profiles. J. Invest. Dermatol. 128, 1797-1805 (2008).
87. Asplund, A. et al. Expression profiling of microdissected cell populations selected from basal cells in normal epidermis and basal cell carcinoma. Br. J. Dermatol. 158, 527-538 (2008).
88. Xie, J. et al. A role of PDGFR? in basal cell carcinoma proliferation. Proc. Natl Acad. Sci. USA 98, 9255-9259 (2001).
89. Bigelow, R. L. et al. Transcriptional regulation of bcl-2 mediated by the sonic hedgehog signaling pathway through gli-1. J. Biol. Chem. 279, 1197-1205 (2004).
90. Regl, G. et al. Activation of the BCL2 promoter in response to Hedgehog/GLI signal transduction is predominantly mediated by GLI2. Cancer Res. 64, 7724-7731 (2004).
91. Kump, E., Ji, J., Wernli, M., Hausermann, P. & Erb, P. Gli2 upregulates cFlip and renders basal cell carcinoma cells resistant to death ligand-mediated apoptosis. Oncogene 27, 3856-3864 (2008).
92. Li, C. et al. IFNα induces Fas expression and apoptosis in hedgehog pathway activated BCC cells through inhibiting Ras-Erk signaling. Oncogene 23, 1608-1617 (2004).
93. Athar, M. et al. Inhibition of smoothened signaling prevents ultraviolet B-induced basal cell carcinomas through regulation of Fas expression and apoptosis. Cancer Res. 64, 7545-7552 (2004).
94. Leung, C. et al. Bmi1 is essential for cerebellar development and is overexpressed in human medulloblastomas. Nature 428, 337-341 (2004).
95. Reinisch, C. M., Uthman, A., Erovic, B. M. & Pammer, J. Expression of BMI-1 in normal skin and inflammatory and neoplastic skin lesions. J. Cutan. Pathol. 34, 174-180 (2007).
96. Kenney, A. M. & Rowitch, D. H. Sonic hedgehog promotes G1 cyclin expression and sustained cell cycle progression in mammalian neuronal precursors. Mol. Cell. Biol. 20, 9055-9067 (2000).
97. Rao, G. et al. Sonic hedgehog and insulin-like growth factor signaling synergize to induce medulloblastoma formation from nestin-expressing neural progenitors in mice. Oncogene 23, 6156-6162 (2004).
98. Hahn, H. et al. Patched target Igf2 is indispensable for the formation of medulloblastoma and rhabdomyosarcoma. J. Biol. Chem. 15, 28341-28344 (2000).
99. Levitt, R. J., Zhao, Y., Blouin, M. J. & Pollak, M. The hedgehog pathway inhibitor cyclopamine increases levels of p27, and decreases both expression of IGF-II and activation of Akt in PC-3 prostate cancer cells. Cancer Lett. 255, 300-306 (2007).
100. Lipinski, R. J. et al. Sonic hedgehog signaling regulates the expression of insulin-like growth factor binding protein-6 during fetal prostate development. Dev. Dyn. 233, 829-836 (2005).
101. Allan, G. J. et al. Major components of the insulin-like growth factor axis are expressed early in chicken embryogenesis, with IGF binding protein (IGFBP)-5 expression subject to regulation by sonic hedgehog. Anat. Embryol. (Berl.) 207, 73-84 (2003).
102. Elia, D., Madhala, D., Ardon, E., Reshef, R. & Halevy, O. Sonic hedgehog promotes proliferation and differentiation of adult muscle cells: involvement of MAPK/ERK and PI3K/Akt pathways. Biochim. Biophys. Acta 1773, 1438-1446 (2007).
103. Riobo, N. A., Lu, K., Ai, X., Haines, G. M. & Emerson, C. P., Jr. Phosphoinositide 3-kinase and Akt are essential for sonic hedgehog signaling. Proc. Natl Acad. Sci. USA 103, 4505-4510 (2006).
104. Teh, M. T. et al. FOXM1 is a downstream target of Gli1 in basal cell carcinomas. Cancer Res. 62, 4773-4780 (2002).
105. Yoshida, Y., Wang, I. C., Yoder, H. M., Davidson, N. O. & Costa, R. H. The forkhead box M1 transcription factor contributes to the development and growth of mouse colorectal cancer. Gastroenterology 132, 1420-1431 (2007).
106. Dai, B. et al. Aberrant FoxM1B expression increases matrix metalloproteinase-2 transcription and enhances the invasion of glioma cells. Oncogene 26, 6212-6219 (2007).
107. Liu, M. et al. FoxM1B is overexpressed in human glioblastomas and critically regulates the tumorigenicity of glioma cells. Cancer Res. 66, 3593-3602 (2006).
108. Kalin, T. V. et al. Increased levels of the FoxM1 transcription factor accelerate development and progression of prostate carcinomas in both TRAMP and LADY transgenic mice. Cancer Res. 66, 1712-1720 (2006).
109. Kim, I. M. et al. The forkhead box m1 transcription factor stimulates the proliferation of tumor cells during development of lung cancer. Cancer Res. 66, 2153-2161 (2006).
110. Tan, Y., Raychaudhuri, P. & Costa, R. H. Chk2 mediates stabilization of the FoxM1 transcription factor to stimulate expression of DNA repair genes. Mol. Cell. Biol. 27, 1007-1016 (2007).
111. Schuller, U. et al. Forkhead transcription factor FoxM1 regulates mitotic entry and prevents spindle defects in cerebellar granule neuron precursors. Mol. Cell. Biol. 27, 8259-8270 (2007).
112. Wonsey, D. R. & Follettie, M. T. Loss of the forkhead transcription factor FoxM1 causes centrosome amplification and mitotic catastrophe. Cancer Res. 65, 5181-5189 (2005).
113. ARF tumor suppressor. Genes Dev. 18, 830-850 (2004).
114. Gusarova, G. A. et al. A cell-penetrating ARF peptide inhibitor of FoxM1 in mouse hepatocellular carcinoma treatment. J. Clin. Invest. 117, 99-111 (2007).
115. Radhakrishnan, S. K. et al. Identification of a chemical inhibitor of the oncogenic transcription factor forkhead box M1. Cancer Res. 66, 9731-9735 (2006).
116. Eichberger, T. et al. FOXE1, a new transcriptional target of GLI2, is expressed in human epidermis and basal cell carcinoma. J. Invest. Dermatol. 122, 1180-1187 (2004).
117. Brancaccio, A. et al. Requirement of the forkhead gene Foxe1, a target of sonic hedgehog signaling, in hair follicle morphogenesis. Hum. Mol. Genet. 13, 2595-2606 (2004).
118. Yang, S. H. et al. Pathological responses to oncogenic Hedgehog signaling in skin are dependent on canonical Wnt/β-catenin signaling. Nature Genet. 40, 1130-1135 (2008).
119. Nilsson, M. et al. Induction of basal cell carcinomas and trichoepitheliomas in mice overexpressing GLI-1. Proc. Natl Acad. Sci. USA 97, 3438-3443 (2000).
120. Grachtchouk, M. et al. Basal cell carcinomas in mice overexpressing Gli2 in skin. Nature Genet. 24, 216-217 (2000).
121. Aszterbaum, M. et al. Ultraviolet and ionizing radiation enhance the growth of BCCs and trichoblastomas in patched heterozygous knockout mice. Nature Med. 5, 1285-1291 (1999).
122. Svard, J. et al. Genetic elimination of Suppressor of fused reveals an essential repressor function in the mammalian Hedgehog signaling pathway. Dev. Cell 10, 187-197 (2006).
123. Grachtchouk, V. et al. The magnitude of hedgehog signaling activity defines skin tumor phenotype. EMBO J. 22, 2741-2751 (2003).
124. Wetmore, C., Eberhart, D. E. & Curran, T. Loss of p53 but not ARF accelerates medulloblastoma in mice heterozygous for patched. Cancer Res. 61, 513-516 (2001).
125. Hadley, M. E. & Dorr, R. T. Melanocortin peptide therapeutics: historical milestones, clinical studies and commercialization. Peptides 27, 921-930 (2006).
126. Gange, R. W., Blackett, A. D., Matzinger, E. A., Sutherland, B. M. & Kochevar, I. E. Comparative protection efficiency of UVA- and UVB-induced tans against erythema and formation of endonucleasesensitive sites in DNA by UVB in human skin. J. Invest. Dermatol. 85, 362-364 (1985).
127. Eller, M. S., Asarch, A. & Gilchrest, B. A. Photoprotection in human skin - a multifaceted SOS response. Photochem. Photobiol. 84, 339-349 (2008).
128. +/- mice. Am. J. Pathol. 172, 1248-1255 (2008).
129. Yarosh, D. B. & Klein, J. DNA repair enzymes in prevention of photocarcinogenesis. Photochem. Photobiol. 63, 445-447 (1996).
130. Yarosh, D. et al. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 357, 926-929 (2001).
131. Peck, G. L. et al. Treatment and prevention of basal cell carcinoma with oral isotretinoin. J. Am. Acad. Dermatol. 19, 176-185 (1988).
132. Goldberg, L. H., Hsu, S. H. & Alcalay, J. Effectiveness of isotretinoin in preventing the appearance of basal cell carcinomas in basal cell nevus syndrome. J. Am. Acad. Dermatol. 21, 144-145 (1989).
133. Kraemer, K. H., DiGiovanna, J. J., Moshell, A. N., Tarone, R. E. & Peck, G. L. Prevention of skin cancer in xeroderma pigmentosum with the use of oral isotretinoin. N. Engl. J. Med. 318, 1633-1637 (1988).
134. Tangrea, J. A. et al. Long-term therapy with low-dose isotretinoin for prevention of basal cell carcinoma: a multicenter clinical trial. J. Natl Cancer Inst. 84, 328-332 (1992).
135. Levine, N.et al. Trial of retinol and isotretinoin in skin cancer prevention: a randomized double-blind, controlled trial. Cancer Epidemiol. Biomarkers Prevention 6, 957-961 (1997).
136. Peris, K., Fargnoli, M. C. & Chimenti, S. Preliminary observations on the use of topical tazarotene to treat basal-cell carcinoma. N. Engl. J. Med. 341, 1767-1768 (1999).
137. Duvic, M. et al. Tazarotene-induced gene 3 is suppressed in basal cell carcinomas and reversed in vivo by tazarotene application. J. Invest. Dermatol. 121, 902-909 (2003).
138. Bianchi, L. et al. Topical treatment of basal cell carcinoma with tazarotene: a clinicopathological study on a large series of cases. Br. J. Dermatol. 151, 148-156 (2004).
139. +/- mice exposed to ultraviolet or ionizing radiation. Cancer Res. 64, 4385-4389 (2004).
140. So, P. L., Fujimoto, M. A. & Epstein, E. H. Jr. Pharmacologic retinoid signaling and physiologic retinoic acid receptor signaling inhibit basal cell carcinoma tumorigenesis. Mol. Cancer Ther. 7, 1275-1284 (2008).
141. Black, H. S. et al. Evidence that a low-fat diet reduces the occurence of non-melanoma skin cancer. Int. J. Cancer 62, 165-169 (1995).
142. Carneiro, B. A., Watkin, W. G., Mehta, U. K. & Brockstein, B. E. Metastatic basal cell carcinoma: complete response to chemotherapy and associated pure red cell aplasia. Cancer Invest. 24, 396-400 (2006).
143. Binns, W., James, L. F., Shupe, J. L. & Everett, G. A congenital cyclopian-type malformation in lambs induced by maternal ingestion of a range plant, Veratrum californicum. Am. J. Vet. Res. 24, 1164-1175 (1963).
144. Tabs, S. & Avci, O. Induction of the differentiation and apoptosis of tumor cells in vivo with efficiency and selectivity. Eur. J. Dermatol. 14, 96-102 (2004).
145. Cooper, M. K., Porter, J. A., Young, K. E. & Beachy, P. A. Teratogen-mediated inhibition of target tissue response to Shh signaling. Science 280, 1603-1607 (1998).
146. Incardona, J. P., Gaffield, W., Kapur, R. P. & Roelink, H. The teratogenic Veratrum alkaloid cyclopamine inhibits sonic hedgehog signal transduction. Development 125, 3553-3562 (1998).
147. Chen, J. K., Taipale, J., Cooper, M. K. & Beachy, P. A. Inhibition of Hedgehog signaling by direct binding of cyclopamine to Smoothened. Genes Dev. 16, 2743-2748 (2002).
148. Taipale, J. et al. Effects of oncogenic mutations in Smoothened and Patched can be reversed by cyclopamine. Nature 406, 1005-1009 (2000).
149. Van Hoff, D. D. et al. Efficacy data of GDC-0449, a systemic Hedgehog (Hh) pathway antagonist, in a first-in-human, first-in-class, phase I study with locally advanced, multifocal or metastatic basal cell carcinoma patients. Proc. 99th Annu. Meeting Am. Assoc. Cancer Res. abstract LB-138 (2008).
150. Palma, V. et al. Sonic hedgehog controls stem cell behavior in the postnatal and adult brain. Development 132, 335-344 (2005).
151. Balordi, F. & Fishell, G. Mosaic removal of hedgehog signaling in the adult SVZ reveals that the residual wild-type stem cells have a limited capacity for selfrenewal. J. Neurosci. 27, 14248-14259 (2007).
152. Zhang, C. L., Zou, Y., He, W., Gage, F. H. & Evans, R. M. A role for adult TLX-positive neural stem cells in learning and behaviour. Nature 451, 1004-1007 (2008).
153. Paladini, R. D., Saleh, J., Qian, C., Xu, G. X. & Rubin, L. L. Modulation of hair growth with small molecule agonists of the hedgehog signaling pathway. J. Invest. Dermatol. 125, 638-646 (2005).
154. Miura, H., Kusakabe, Y. & Harada, S. Cell lineage and differentiation in taste buds. Arch. Histol. Cytol. 69, 209-225 (2006).
155. Angot, E. et al. Chemoattractive activity of sonic hedgehog in the adult subventricular zone modulates the number of neural precursors reaching the olfactory bulb. Stem Cells 10 Jul 2008 [epub ahead of print].
156. Kimura, H., Ng, J. M. & Curran, T. Transient inhibition of the Hedgehog pathway in young mice causes permanent defects in bone structure. Cancer Cell 13, 249-260 (2008).
157. Arad, S., Konnikov, N., Goukassian, D. A. & Gilchrest, B. A. Quantification of inducible SOS-like photoprotective responses in human skin. J. Invest. Dermatol. 127, 2629-2636 (2007).
158. Bijlsma, M. F. et al. Repression of smoothened by patched-dependent (pro-)vitamin D3 secretion. PLoS Biol. 4, e232 (2006).
159. Holick, M. F. et al. Photosynthesis of previtamin D3 in human skin and the physiologic consequences. Science 210, 203-205 (1980).
160. MacLaughlin, J. & Holick, M. F. Aging decreases the capacity of human skin to produce vitamin D3. J. Clin. Invest. 76, 1536-1538 (1985).
161. +/- mice. J. Invest. Dermatol. 124, 263-267 (2005).
162. Karhadkar, S. S. et al. Hedgehog signalling in prostate regeneration, neoplasia and metastasis. Nature 431, 707-712 (2004).
163. Van Scott, E. J. & Reinertson, R. P. The modulating influence of stromal environment on epithelial cells studies in human autoransplants. J. Invest. Dermatol. 36, 109-131 (1961).
164. Williams, T. et al. The oncogenic GLI (GLI1 and GLI2) transcription factors induce characteristics of cellular senescence in N/Tert-1 keratinocytes. J. Invest. Dermatol. 127, s92 (2007).
165. Gorlin, R. J. Nevoid basal-cell carcinoma syndrome. Medicine (Baltimore) 66, 98-113 (1987).
166. Evans, D. G. R., Farndon, P. A., Burnell, L. D., Gattamaneni, H. R. & Birch, J. M. The incidence of Gorlin syndrome in 173 consecutive cases of medulloblastoma. Br. J. Cancer 64, 959-961 (1991).
167. Johnson, A. D., Hebert, A. A. & Esterly, N. B. Nevoid basal cell carcinoma syndrome: bilateral ovarian fibromas in a 3 1/2-year-old girl. J. Am. Acad. Dermatol. 14, 371-374 (1986). References 165-167 review the clinical aspects of BCNS.
168. Kimonis, V. E. et al. Clinical manifestations in 105 persons with nevoid basal cell carcinoma syndrome. Am. J. Med. Genet. 69, 299-308 (1997).
169. Miller, K. L. et al. XPA, haplotypes, and risk of basal and squamous cell carcinoma. Carcinogenesis 27, 1670-1675 (2006).
170. Kang, S. Y. et al. Polymorphisms in the DNA repair gene XRCC1 associated with basal cell carcinoma and squamous cell carcinoma of the skin in a Korean population. Cancer Sci. 98, 716-720 (2007).
171. Han, J., Hankinson, S. E., Colditz, G. A. & Hunter, D. J. Genetic variation in XRCC1, sun exposure, and risk of skin cancer. Br. J. Cancer 91, 1604-1609 (2004).
172. Dybdahl, M., Vogel, U., Frentz, G., Wallin, H. & Nexo, B. A. Polymorphisms in the DNA repair gene XPD: correlations with risk and age at onset of basal cell carcinoma. Cancer Epidemiol. Biomarkers Prev. 8, 77-81 (1999).
173. Lovatt, T. et al. Polymorphism in the nuclear excision repair gene ERCC2/XPD: association between an exon 6-exon 10 haplotype and susceptibility to cutaneous basal cell carcinoma. Hum. Mutat. 25, 353-359 (2005).
174. Vogel, U. et al. Effect of polymorphisms in XPD, RAI, ASE-1 and ERCC1 on the risk of basal cell carcinoma among Caucasians after age 50. Cancer Detect. Prev. 29, 209-214 (2005).
175. Han, J., Colditz, G. A. & Hunter, D. J. Lack of associations of selected variants in genes involved in cell cycle and apoptosis with skin cancer risk. Cancer Epidemiol. Biomarkers Prev. 15, 592-593 (2006).
176. Lin, Q. et al. Increased susceptibility to UV-induced skin carcinogenesis in polymerase eta-deficient mice. Cancer Res. 66, 87-94 (2006).
177. Meeran, S. M., Mantena, S. K., Meleth, S., Elmets, C. A. & Katiyar, S. K. Interleukin-12-deficient mice are at greater risk of UV radiation-induced skin tumors and malignant transformation of papillomas to carcinomas. Mol. Cancer Ther. 5, 825-832 (2006).
178. Schwarz, T. Photoimmunosuppression. Photodermatol. Photoimmunol. Photomed. 18, 141-145 (2002).
179. Reynolds, N. J., Todd, C. & Angus, B. Overexpression of protein kinase C-α and -β isozymes by stromal dendritic cells in basal and squamous cell carcinoma. Br. J. Dermatol. 136, 666-673 (1997).
180. Neill, G. W. et al. Loss of protein kinase Cα expression may enhance the tumorigenic potential of Gli1 in basal cell carcinoma. Cancer Res. 63, 4692-4697 (2003).
181. Riobo, N. A., Haines, G. M. & Emerson, C. P. Jr. Protein kinase C-δ and mitogen-activated protein/extracellular signal-regulated kinase-1 control GLI activation in hedgehog signaling. Cancer Res. 66, 839-845 (2006).
182. Lauth, M., Bergstrom, A. & Toftgard, R. Phorbol esters inhibit the Hedgehog signalling pathway downstream of Suppressor of Fused, but upstream of Gli. Oncogene 26, 5163-5168 (2007).
183. +/- mice. J. Clin. Invest. 113, 867-875 (2004).
184. Thyberg, J. & Fredholm, B. B. Induction of ornithine decarboxylase activity and putrescine synthesis in arterial smooth muscle cells stimulated with platelet-derived growth factor. Exp. Cell Res. 170, 160-169 (1987).
185. Kasper, M. et al. Selective modulation of Hedgehog/GLI target gene expression by epidermal growth factor signaling in human keratinocytes. Mol. Cell. Biol. 26, 6283-6298 (2006).
186. Mimeault, M. et al. Combined targeting of epidermal growth factor receptor and hedgehog signaling by gefitinib and cyclopamine cooperatively improves the cytotoxic effects of docetaxel on metastatic prostate cancer cells. Mol. Cancer Ther. 6, 967-978 (2007).
187. Ikeuchi, T., Urano, Y., Fukuhara, K., Nakanishi, H. & Arase, S. Light microscopic autoradiographical analysis of [125I]epidermal growth factor
188. Mimeault, M. et al. Cytotoxic effects induced by a combination of cyclopamine and gefitinib, the selective hedgehog and epidermal growth factor receptor signaling inhibitors, in prostate cancer cells. Int. J. Cancer 118, 1022-1031 (2006).
189. Hu, W. G., Liu, T., Xiong, J. X. & Wang, C. Y. Blockade of sonic hedgehog signal pathway enhances antiproliferative effect of EGFR inhibitor in pancreatic cancer cells. Acta Pharmacol. Sin. 28, 1224-1230 (2007).
190. Neill, G. W. et al. GLI1 repression of ERK activity correlates with colony formation and impaired migration in human epidermal keratinocytes. Carcinogenesis 29, 738-746 (2008).
191. Dennler, S. et al. Induction of sonic hedgehog mediators by transforming growth factor-β: Smad3-dependent activation of Gli2 and Gli1 expression in vitro and in vivo. Cancer Res. 67, 6981-6986 (2007).
192. Stamp, G. W. et al. Transforming growth factor-β distribution in basal cell carcinomas: relationship to proliferation index. Br. J. Dermatol. 129, 57-64 (1993).
193. Gambichler, T. et al. Increased expression of TGF-β/Smad proteins in basal cell carcinoma. Eur. J. Med. Res. 12, 509-514 (2007).
194. Verhaegh, M. E., Arends, J. W., Majoie, I. M., Hoekzema, R. & Neumann, H. A. Transforming growth factor-β and bcl-2 distribution patterns distinguish trichoepithelioma from basal cell carcinoma. Dermatol. Surg. 23, 695-700 (1997).
195. Lange, D. et al. Expression of TGF-β related Smad proteins in human epithelial skin tumors. Int. J. Oncol. 14, 1049-1056 (1999).
196. Sneddon, J. B. et al. Bone morphogenetic protein antagonist gremlin 1 is widely expressed by cancer-associated stromal cells and can promote tumor cell proliferation. Proc. Natl Acad. Sci. USA 103, 14842-14847 (2006).
197. Thelu, J., Rossio, P. & Favier, B. Notch signalling is linked to epidermal cell differentiation level in basal cell carcinoma, psoriasis and wound healing. BMC Dermatol. 2, 7 (2002).
198. Nicolas, M. et al. Notch1 functions as a tumor suppressor in mouse skin. Nature Genet. 33, 416-421 (2003).
199. Christenson, L. J. et al. Incidence of basal cell and squamous cell carcinomas in a population younger than 40 years. JAMA 294, 681-690 (2005).